3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Melanoma
1
Epidermolysis Bullosa Dystrophica
1
Carcinoma, Squamous Cell
1
Interventions
pembrolizumab
25
Cisplatin
20
Carboplatin
14
Paclitaxel
11
Radiotherapy
9
Radiotherapy, Intensity-Modulated
8
Docetaxel
8
Cetuximab
8
Nivolumab
7
cemiplimab
5
Radiation
5
durvalumab
4
atezolizumab
3
Taxes
3
Surveys and Questionnaires
3
Fluorouracil
3
Drug Therapy
3
Cyclophosphamide
3
Blood Specimen Collection
3
toripalimab
2
olaparib
2
fludarabine
2
avelumab
2
alpha-2'-deoxythioguanosine
2
aldesleukin
2
Surgical Procedures, Operative
2
Standard of Care
2
Pemetrexed
2
Magnetic Resonance Spectroscopy
2
vistusertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Squamous Cell
×
ON 01910
×
1 year
×
Clear all
NCT03786237
2026-02-24
Rigosertib for RDEB-SCC
Salzburger Landeskliniken
Phase 1/2
Completed
2 enrolled